Member Info for VanVan

The share register is impressive for such a small Co. but I don't believe Jeremy holds many shares which makes him more of a Manager than an owner. At these margin prices surely he and the rest of the Board should be buying to show there confidence in the project. Its as though no one believes that the Nickel seize is coming, or is it because our product will be for the none sexy stainless steel market. Someone imo is going to do very nicely buying into such a cast iron (sorry) project as this under 3p.

This is my recent post on ADVFN:
If I was in charge of video production (ha ha)I'd include our differentiators or if you like the facts that makes us stand out like:-
1. Global JORC Resource of 1.6m oz plus an Exploration Target showing the potential for an additional 2.7mozs of gold and 16m ozs of Silver.
2. Production results from Kiziltepe mine exceed plan - better grades, lower costs etc.
3. Lowest quartile operating costs - below $400 per oz.
4.Potential to double life of mine and double production as Tavsan with 80% IRR comes on board.
5. Debt free in less than 18 months.
6. Lowest quartile cost of discovery of c. $15 per oz.
7. More than 6 Exploration sites under development (Salinbas, Ardala, Kepez, Tavsan, Kizilcukur, Ivrindi etc.
8. Significantly undervalued with a Market Cap. less than the value of just Salinbas!
9. Seamless transition from commissioning to full production and exemplary Safety records.
I could go on and bore everyone to sleep!

I’m pleased to see a few positive posters because from my brief knowledge so no expert, I’m impressed. The way I see it is the Oncology sector is very hot right now and the big boys not only want but need to ensure they have a slice of the action. If the Modi-1 clinical trials play out to endorse findings do far this will surely be mega.But I don’t think they can afford to wait for cast iron endorsements, I think many will already be doing DD on Scancell, but of course just imo.
The current share price is irrelevant in the scheme of things. It is only where it is due largely to pte shareholders not understanding where the Co. is and what has been achieved. Next week is going to be very helpful in rebuilding that understanding with the AGM & then the Investors evening. I wish the Co. the BofD all shareholders & people with cancer that they can give hope to the very best for the future.

Now under 10. Cheap or what?

Do the Directors mingle after the formal part?
Or do they try and escape ASAP.

I'd just like to say how sorry I am for those with cancer who are effected by this delay. It must be a nightmare for them.
Let's hope this issue can be resolved asap as for some it could mean the difference of life or death.
Sorry to be morbid, but with a Co. (investment) we always have to get matters in perspective.

6.30 this evening at Hammersmith - meet the team. Can't go but hope we get some feedback.

"We are also carefully evaluating a few opportunities outside of the current portfolio that have the potential to strengthen and diversify the Company in terms of commodity and geography, as part of our core strategy to future-proof the business and unlock value for shareholders. We look forward to keeping the market updated on our progress across our exploration and development portfolio in the coming months."

Quarterlies due mid November I believe.

I’m happy with that Botski. Thanks for your help.

Botski- thanks for confirming you agree we are talking here about survival rates not just The suitability issue.
I know it is early days and it’s just mice ,but as you say even 50% survival would be beyond Mostar wildest dreams.
The importance of accelerating the trials to prove this cannot be understated. I think the trials are too small and would benefit perhaps from support from Genentech (Roche).
But this has to be an exciting point. I wonder what more will be revealed at the AGM?
If anyone thinks we are still misinterpreting this slide, please shout. Thanks.

This is from the slide. Sorry it was actually slide 17 not 15. Anyway here ii is and please see words at bottom. 100% survival rate.
Modi-1
 Consists of:
 Two citrullinated vimentin peptides (Vim-1 and Vim-2)
 One citrullinated enolase peptide (Eno-1)
 Vimentin and enolase targets are highly expressed in triple negative breast cancer (90%), ovarian
cancer (95%), and sarcoma (100%) - all with high unmet medical need
 Modi-1 induced potent anti-tumour responses in mice with established melanoma (B16)  A single immunization of Modi-1 resulted in a 100% survival rate in animal models

The use of the word "survival" is confusing me.

"A single immunisation of Modi-1 resulted in a 100% survival rate" . You can perhaps see from the word "survival" how easy it is to get mislead. Why would they use that word?

I've realised I now need to ask you another question! Oh now I hear you saw! Sorry.
Slide 15 of the Scancell presentation titles "The Moditope Platform" showed the 90% "highly expressed" etc. but also in bold said: "A single immunisation of Modi-1 resulted in a 100% survival rate" . You can perhaps see from the word "survival" how easy it is to get mislead. Why would they use that word?

My main question is, am I to understand that PD-L1 is a "checkpoint inhibitor"?

What I think you are saying is still pretty significant for Scancell, in that up until now only those 20% of TNBC patients who are likely to have tumours with high levels of PD-L1 expression (I'm using the right words ha ha, even though it is jargon to me!) could expect to respond better to checkpoint inhibitors.
Now we discovery, that for some reason using the Scancell, Modi-1 treatment, unprecendented anti-tumour effects can be delivered without the need for checkpoint inhibitors.
So your very important point Bermuda - "So you can see that the target market for Tecentriq is likely to be about 20% of patients whereas Modi1 would be 90%*.
This seems a significant difference. If we have such a clear USP, then surely Modi-1 must be a highly valuable piece of intellectual property.
Sorry to labour this out, but I can't believe the industry (competitors) isn't already sniffing around what Scancell have potentially developed here. Has this USP been known about for long?

Bermudashorts: What a great response. Oh how easy as a greenhorn it is to add 2 plus 2 and arrive at 5.
I can see how one is looking for the positives and not reading the words literally as it is now very clear.
The following result, as you point out, is still very significant for Modi-1.

"So you can see that the target market for Tecentriq is likely to be about 20% of patients whereas Modi1 would be 90%".
Thanks again for the clear explanation.

You draw out some interesting observations ratcliffewriter. I would be of the opinion that M&A activity in this tight field is highly likely/inevitable. Just a matter of time.
I can't see minnow Scancell being left independent if they potentially have something that could be transformational.
As I highlighted in my earlier post, I can't square yet, how Scancell's pre clinical trials seem to be producing life expectancy results that are in a different league to this 902 patient study across 246 medical centres in 41 countries.
If Scancell has found even a hint of the holy grail they will be gobbled up in no time imo. But I can't believe our results can potentially be so good without the world already jumping up and down. What am I missing here?

Thanks for the article but I found the results rather depressing. Not much improvement in life terms ( 25 months compared to 15.5 months) plus massive cost - £100,000 and potential strong side effects.
How does that sit alongside the stunning results Scancell had with the pre human studies with Modi-1.
Quote: "Pre-clinical data suggests that Modi-1 may be effective in up to 90% of patients with TNBC, up to 95% of patients with ovarian cancers and up to 100% of patients with sarcoma"
Is the PD-L1 market relevant to our studies do we know please?
It interesting how all these Co's seems to be collaboration. Genentech (member of Roche Group who in turn are focussed on personalised cancer vaccines) and BioNtech who Scancell are working with.

Anyone going on Tuesday? Hoping for some feedback.
I think by now they ought to be able to provide some sort of project plan for LC, showing key stages including
commissioning/trial production, production etc.
Any chance of more Director share purchase to demonstrate their belief that the shares are undervalued I wonder.
How much would it cost us to invest in a new copper process. Don’t see how that fits with our business model. Perhaps they will say more on Tuesday. Strange one imo.

Thanks Chester. Much appreciated

Could someone please help me as a greenhorn understand what this means in very simple idiot proof language - "without the need for checkpoint inhibitors". What is the significance?
Thanks

Have you seen the latest picture on Twitter?
One to drool over for sure!
Excellent potential for mineralisation exposed along some of the new road cuts within Ardala North at the Salinbas Project #AAU #gold #mine